Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Solid Carcinoma: early-phase trial registry
6 of 9 indexed Solid Carcinoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,916 of 28,707 conditions by registered trial count.
9 US clinical trials · 6 currently recruiting · #1,916 of 28,707 conditions by registered trial count
Solid Carcinoma: 9 US clinical trials tracked, 6 recruiting.
Solid Carcinoma is the subject of 9 registered US clinical trials on ClinicalTrials.gov, 6 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most active sponsor is Xadcera Biopharmaceutical (Suzhou) Co., running 2 of these trials.
Enrollment posture brief
Registry condition solid-carcinoma
OPEN 6 | RECR 67% | LATE 0 | EARLY 9 | RANK #1916 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Acute Hypoxemic Respiratory Failure (67% recruiting · 6 trials)
Solid Carcinoma lists 6 open slots (67% of 9 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Solid Carcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Solid Carcinoma is recruiting above its size-band peers.
6 of 9 indexed trials (66.7%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Solid Carcinoma research.
Xadcera Biopharmaceutical (Suzhou) Co. accounts for 2 of 9 trials (22.2%). 7 distinct sponsors appear on at least one study for this condition label.
-
Most Solid Carcinoma trials plan to enrol fewer than 100 people.
Median target enrolment is 78 among the 9 trials that report a genuine target (sentinel values excluded). 6 of those (66.7%) plan for fewer than 100 participants.
-
Solid Carcinoma research is mostly interventional.
9 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
9 total, page 1 of 1
A Study of DM002 in Patients With Advanced Solid Tumors
Xadcera Biopharmaceutical (Suzhou) Co.
NCT06751329
A Study of DM005 in Patients With Advanced Solid Tumors
Doma Biopharmaceutical（Suzhou）Co.
NCT06515990
A Study of DM001 in Patients With Advanced Solid Tumors
Xadcera Biopharmaceutical (Suzhou) Co.
NCT06475937
An Open-Label Study of INV-1120 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors
Shenzhen Ionova Life Sciences Co.
NCT04443088
Imaging of Solid Tumors Using 18F-TRX
Rahul Aggarwal
NCT06942104
PET [89Zr]DFO-starPEG in Solid Tumors
Robert Flavell, MD, PhD
NCT06894745
A Study of AZD1390 and Stereotactic Body Radiotherapy (SBRT) for People With Metastatic Solid Tumor Cancer
Memorial Sloan Kettering Cancer Center
NCT05678010
Study of Benralizumab in People With Skin Side Effects Caused by Cancer Therapies
Memorial Sloan Kettering Cancer Center
NCT04552288
A Phase 1a/b Study of IK-175 as a Single Agent and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors and Urothelial Carcinoma
Ikena Oncology
NCT04200963
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 8 |
| Phase 2 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Solid Carcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Solid Carcinoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Solid Carcinoma page
9 registered trials, 6 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 6 Solid Carcinoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Xadcera Biopharmaceutical (Suzhou) Co. sponsors the most Solid Carcinoma trials on record, review their full trial history before evaluating a specific study. See Xadcera Biopharmaceutical (Suzhou) Co.'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Solid Carcinoma condition card totals 9 registered trials; most-linked intervention IK-175 and nivolumab; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.